Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4590 Association of SST5TMD4 and SST5TMD5 expression with metastasis and poor prognostic markers in gastroenteropancreatic neuroendocrine tumours

Introduction: The expression of the somatostatin receptor isoform SST5TMD4 is linked to poorer prognosis in somatotropinomas, as well as in breast and thyroid cancers, and it is notably overexpressed in gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Conference:

Presenting Author: Pedraza-Arevalo S

Authors: Pedraza-Arévalo S, Díaz-Pérez J, Garcia-Carbonero R, Villabona C, Capdevila J,

Keywords: GEP-NET, somatostatin, truncated receptor, metastasis,

#4574 Long-acting somatostatin analogue injections for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and acromegaly: BackSOM – A patient preference study

Introduction: Long-acting somatostatin analogues, lanreotide and octreotide, are indicated for first-line treatment of GEP-NETs and acromegaly. Lanreotide was approved in 2007 in Europe, and is supplied as a prefilled, ready-to-use syringe (LAN-PF). In 2021, a generic form of lanreotide was released and supplied in a syringe requiring assembly (LAN-RA). To ensure patient compliance with treatment, it is important to understand their injection experiences.

Conference:

Presenting Author: Hernando Cubero J

Authors: Rodien-Louw C, Simo-Servat A, Dubois M, Sheppard J, McDonnell M,

Keywords: gastroenteropancreatic neuroendocrine tumour, GEP-NET, acromegaly, lanreotide, LA-SSA, somatostatin, patient preference,

#4431 Systemic treatment in metastatic pheochromocytomas and paragangliomas: Optimal moment for starting and outcomes of a multicentre Spanish cohort

Introduction: Pheochromocytomas (PHEOs) and paragangliomas (PGLs), collectively referred to as PPGLs, are relatively rare endocrine tumours with significant clinical variability and metastatic behaviour. Treatment strategies must be tailored individually due to the heterogeneity in their behaviour.

Conference:

Presenting Author: Del Olmo-García M

Authors: Hernández-Rienda L, Contreras-Saldarriaga J, Hernando Cubero J, García Alvarez A, Prado-Wohlwend S,

Keywords: Pheochromocytoma, paraganglioma, PPGL, metastatic, SSA, Radionuclide, chemotherapy,

#4072 Just a matter of weight? Final results from NUTRIGETNE study in patients with Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)

Introduction: Cancer and its treatment may have a dual impact on nutrition and physical performance.

Conference:

Presenting Author: Argente Pla M

Authors: Argente Pla M, Hernandez-Rienda L, Antón-Pascual B, Hernando J, Custodio A,

Keywords: Gastroenteropancreatic, Neuroendocrine Neoplasm, Malnutrition,

#4069 Impact of nutritional status in the quality of life (QoL) of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain: NUTRIGETNE Study

Introduction: Prevalence of malnutrition and sarcopenia is high among patients with advanced GEP-NENs and may significantly decrease response to therapy and impair QoL.

Conference:

Presenting Author:

Authors: Del Olmo-García M, Garcia-Carbonero R, Hernando J, Pérez-Wert P, Suarez Gutiérrez L,

Keywords: nutritional status, Gastroenteropancreatic, Neuroendocrine neoplasm, Sarcopenia, Malnutrition,